Cached score snapshot

US.PFE · Pfizer

110分制 65.8/110;5D動能v2 30/50;排序分 95.8/160

Ranking score 95.8/160
Main score 65.8/110
5D momentum v2 30/50
Rank #13
Setup grade B 77.2

Score breakdown

觀望

Low database-backfill

Score and price trend

B 77.2 Technical S · Money flow A · lift 1.49x

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 01-02 02-19 04-07 05-21 07-08 $23.21$26.19$29.16 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 1.555 · anchors 40 -0.77% -2.07% / +0.82% 33.8% 5% Actual -0.23% · vs median +0.54% · inside 25-75 band
Historical projection 10D n=160 -0.44% -1.94% / +1.20% 41.3% 5% Actual +4.19% · vs median +4.63% · inside 25-75 band

歷史情境統計基於已存檔相似 setup;圖中投影中位線為統計中位數的線性插值展示,並非價格路徑預測或買賣建議。

2026-01-02 → 2026-07-08 · 128 archived points · 3 Improving turn signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 95.8
Display grade 觀望
Model version cursor_18_27_news_v2_160
Main score 65.8/110 (觀望)
5D momentum v2 30/50 (強)
Score with momentum v2 95.8/160 (觀察)
Risk level Low

Audit trace

Full calculation detail

Calculation detail · 8 sections

Market inputs

Bar count 150
ma20 25.49
ma50 25.4316
close 26.5
prevClose 25.88
avgVolume20 47040705
volumeRatio 1.61
changePercent 2.4

Metrics snapshot

close 26.5
volume 75575400
changePercent 2.4

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 65.8/110
Main rating 觀望
5D momentum v2 30/50
Score with momentum v2 95.8/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 2.8/5 · 較差

Dimension score 2.8/5
Dimension grade 較差

Sub-items

pbPoints 0.5
pePoints 0.5
epsPoints 0
roePoints 0
debtPoints 0.4
marginPoints 0
turnoverUsdM 2002.7481
volumePoints 0.5
revenuePoints 0
dividendPoints 0.4
marketCapPoints 0.5

資金流 — 14.8/20 · 良好

Dimension score 14.8/20
Dimension grade 良好

Sub-items

cmfPoints 2.4
mfiPoints 2.4
obvPoints 4
vwapPoints 4

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.PFE
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 10.2/15 · 一般

Dimension score 10.2/15
Dimension grade 一般

Sub-items

vix

score 2.4

details

source twelvedata+fred+database-backfill-market-proxy
vixClose 16.35

trend

score 4

details

qqq

ma20 122.3286
ma50 119.9635
name QQQ
close 124.1371
points 2

spy

ma20 113.2769
ma50 110.8728
name SPY
close 114.4549
points 2
source twelvedata+fred+database-backfill-market-proxy
atrPct 2.0457
atrPoints 3
cciPoints 0.8
vixPoints 2.4
marketTrendPoints 4

催化劑 — 2/20 · 較差

Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source fmp_stable_news_keyword_model_empty
articleCount 0
catalystCount 0
catalystPoints 2

風險管理 — 8.2/10 · 優秀

Dimension score 8.2/10
Dimension grade 優秀

Sub-items

position

score 1.8

details

atrPct 2.0457
turnoverUsdM 2002.7481
liquidityPoints 0.8
volatilityPoints 1
rrPoints 2

stopLevels

symbol US.PFE
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 25.4158

strength_details

ma_score 2
atr_score 2
rsi_score 3
macd_score 3
volume_score 2
market_adjustment 1
risk_reward_ratio 1.8
stop_loss_percent 4.1
take_profit_price 28.4479
target_multiplier 2.2
technical_strength 2.45
take_profit_percent 7.4
positionPoints 1.8
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.8087
stopLossPercent 4.0913
diversificationPoints 2

技術信號 — 25.8/30 · 優秀

Dimension score 25.8/30
Dimension grade 優秀

Sub-items

bbPoints 3
adxPoints 3
sarPoints 2.4
vcpPoints 2.6
macdPoints 4

vcpPayload

vcp_pass false
vcp_score 2.6
vcp_reason 波幅收縮(6.9%→5.1%);站上MA50;升放量(近10日3日);收盤突破20日高位;Ready=N;Confirm=Y

vcp_metrics

up_days 5
vol_ref 48125666.6667
down_days 4
vcp_ready false
above_ma50 true
avg_vol_10 50580190
avg_vol_20 44342825
avg_vol_30 48125666.6667
range_pct_10 0.0506
range_pct_20 0.0558
range_pct_30 0.0687
up_expand_ok true
lookback_used 79
near_20d_high true
contraction_ok true
down_shrink_ok false
up_expand_days 3
breakout_20d_ok true
vol_ratio_10_30 1.051
dist_to_20d_high -0.0072
down_shrink_days 2
breakout_level_20d 26.31
vcp_breakout_confirm true
contraction_ratio_10_30 0.7363
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction true
kdjAdxPoints 0.8
rsiKdjPoints 4
volumeWeight 2
maCrossPoints 2.4
shortRsiPoints 1
shortMacdPoints 0.4
volConfirmPoints 1
volumePointsTechnical 1.2

情緒分析 — 2/10 · 較差

Dimension score 2/10
Dimension grade 較差

Sub-items

sentiment

score 2

details

source fmp_stable_news_keyword_model_empty
articleCount 0
negativeHits 0
positiveHits 0
sentimentScoreRaw 0

sentimentData

raw
raw_source {"url":"https://seekingalpha.com/article/4916587-jabil-stock-ai-growth-working-valuation-less-forgiving-rating-downgrade","site":"seekingalpha.com","text":"Jabil is downgraded to hold as valuation has rerated to ~23x NTM PE, near its 10-year high. AI-driven revenue growth remains robust, with management guiding for ~$13.6B in FY2026 AI revenue, up 50% year-over-year. JBL's third hyperscaler win and expanded capacity underpin a credible path to >6% operating margin in FY2027.","image":"https://images.financialmodelingprep.com/news/jabil-ai-growth-is-working-but-valuation-is-less-20260621.jpg","title":"Jabil: AI Growth Is Working, But Valuation Is Less Forgiving (Rating Downgrade)","symbol":"JBL","publisher":"Seeking Alpha","publishedDate":"2026-06-21 23:23:58"}, {"url":"https://www.globenewswire.com/news-release/2026/06/22/3315020/673/en/ROSEN-A-LEADING-INVESTOR-RIGHTS-LAW-FIRM-Encourages-Verra-Mobility-Corporation-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-VRRM.html","site":"globenewswire.com","text":"NEW YORK, June 21, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Verra Mobility Corporation (NASDAQ: VRRM) between February 24, 2026 and May 26, 2026, inclusive (the “Class Period”), of the important August 4, 2026 lead plaintiff deadline.","image":"https://images.financialmodelingprep.com/news/rosen-a-leading-investor-rights-law-firm-encourages-verra-20260621.jpg","title":"ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Verra Mobility Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - VRRM","symbol":"LAW","publisher":"GlobeNewsWire","publishedDate":"2026-06-21 23:20:00"}, {"url":"https://www.fool.com/investing/2026/06/21/could-broadcom-be-the-best-way-to-invest-in-artifi/","site":"fool.com","text":"Broadcom is benefiting as hyperscalers shift toward custom AI chips and networking solutions. AI semiconductor revenue hit $10.8 billion, up 143% year over year in fiscal 2026's second quarter.","image":"https://images.financialmodelingprep.com/news/could-broadcom-be-the-best-way-to-invest-in-20260621.jpg","title":"Could Broadcom Be the Best Way to Invest in Artificial Intelligence Right Now?","symbol":"AVGOP","publisher":"The Motley Fool","publishedDate":"2026-06-21 23:00:00"}, {"url":"https://seekingalpha.com/article/4916584-upstart-improving-investment-setup-at-a-10x-pe","site":"seekingalpha.com","text":"Upstart remains a 'Strong Buy' as I expect a multi-year EBITDA upswing driven by AI-powered loan origination and eventual Fed rate cuts. UPST's Q1 transaction volumes surged 61% year-over-year to $3.4B, fueling a 44% Y/Y revenue increase and highlighting robust platform scale. Despite delayed Fed rate cuts, UPST trades at a 44% discount to Fintech peers and a 54% discount to its 3-year average P/E, offering significant revaluation potential if rates fall.","image":"https://images.financialmodelingprep.com/news/upstart-improving-investment-setup-at-a-10x-pe-20260621.jpg","title":"Upstart: Improving Investment Setup At A 10x P/E","symbol":"UPST","publisher":"Seeking Alpha","publishedDate":"2026-06-21 22:53:00"}, {"url":"https://www.globenewswire.com/news-release/2026/06/22/3315016/673/en/REGENCELL-DEADLINE-ROSEN-A-LEADING-LAW-FIRM-Encourages-Regencell-Bioscience-Holdings-Limited-Investors-with-Losses-in-Excess-of-100K-to-Secure-Counsel-Before-Important-June-23-Dead.html","site":"globenewswire.com","text":"NEW YORK, June 21, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”), of the important June 23, 2026 lead plaintiff deadline.","image":"https://images.financialmodelingprep.com/news/regencell-deadline-rosen-a-leading-law-firm-encourages-regencell-20260621.jpg","title":"REGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action – RGC","symbol":"LAW","publisher":"GlobeNewsWire","publishedDate":"2026-06-21 22:37:00"}, {"url":"https://www.globenewswire.com/news-release/2026/06/22/3315015/673/en/ROSEN-GLOBAL-INVESTOR-COUNSEL-Encourages-Microsoft-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-MSFT.html","site":"globenewswire.com","text":"NEW YORK, June 21, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Microsoft Corporation (NASDAQ: MSFT) between May 1, 2025 and January 28, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 11, 2026.","image":"https://images.financialmodelingprep.com/news/rosen-global-investor-counsel-encourages-microsoft-investors-to-secure-20260621.jpg","title":"ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Microsoft Investors to Secure Counsel Before Important Deadline in Securities Class – MSFT","symbol":"MSFT","publisher":"GlobeNewsWire","publishedDate":"2026-06-21 22:34:00"}, {"url":"https://seekingalpha.com/article/4916579-bdj-discount-provides-a-buy-level-for-this-monthly-payer","site":"seekingalpha.com","text":"BlackRock Enhanced Equity Dividend Fund offers diversified, value-oriented exposure with a covered call strategy and an 8.12% yield. BDJ's current -8.22% discount is wider than its historical average, presenting a compelling entry point for income-focused investors. The fund actively manages sector allocations, maintaining financials as its largest sector while increasing technology exposure and selectively capturing gains.","image":"https://images.financialmodelingprep.com/news/bdj-discount-provides-a-buy-level-for-this-monthly-20260621.jpg","title":"BDJ: Discount Provides A 'Buy' Level For This Monthly Payer","symbol":"BDJ","publisher":"Seeking Alpha","publishedDate":"2026-06-21 22:33:00"}, {"url":"https://seekingalpha.com/article/4916581-enbridge-stock-boring-beautiful-cash-flow-growth-accelerates-maintain-buy","site":"seekingalpha.com","text":"Enbridge offers stable, predictable earnings and prioritizes long-term EBITDA growth supporting consistent shareholder returns over capital gains. Q1 2026 results showed flat adjusted EBITDA year-over-year at C$5.81B, with segment performance mixed but distributable cash flow per share up despite forex headwinds. Management reaffirmed 2026 guidance: C$20.2–C$20.8B EBITDA (8% CAGR since 2023) and C$5.70–C$6.10 DCF/share, targeting 5% annual medium-term growth.","image":"https://images.financialmodelingprep.com/news/enbridge-boring-is-beautiful-as-cash-flow-growth-accelerates-20260621.jpg","title":"Enbridge: Boring Is Beautiful As Cash Flow Growth Accelerates","symbol":"ENB","publisher":"Seeking Alpha","publishedDate":"2026-06-21 22:32:20"}, {"url":"https://seekingalpha.com/article/4916578-henry-schein-smile-because-the-upside-isnt-over","site":"seekingalpha.com","text":"Henry Schein remains a dominant global provider in dental and medical practitioner supplies, with strong market shares and ongoing revenue growth. HSIC's Q1 2026 revenue grew 6.3% year-over-year, driven by robust global dental merchandise and equipment demand, particularly in aging and expanding populations. Profitability metrics are mixed, but adjusted net income and EBITDA are rising; management guides for 3–5% revenue growth and mid-single-digit EBITDA growth in 2026.","image":"https://images.financialmodelingprep.com/news/henry-schein-smile-because-the-upside-isnt-over-20260621.jpg","title":"Henry Schein: Smile Because The Upside Isn't Over","symbol":"HSIC","publisher":"Seeking Alpha","publishedDate":"2026-06-21 22:23:00"}, {"url":"https://seekingalpha.com/article/4916569-cynata-therapeutics-limited-cyynf-discusses-phase-ii-acute-graft-versus-host-disease-and","site":"seekingalpha.com","text":"Cynata Therapeutics Limited (CYYNF) Discusses Phase II Acute Graft Versus Host Disease and Phase III Osteoarthritis Trial Results Transcript","image":"https://images.financialmodelingprep.com/news/cynata-therapeutics-limited-cyynf-discusses-phase-ii-acute-graft-20260621.jpg","title":"Cynata Therapeutics Limited (CYYNF) Discusses Phase II Acute Graft Versus Host Disease and Phase III Osteoarthritis Trial Results Transcript","symbol":"CYYNF","publisher":"Seeking Alpha","publishedDate":"2026-06-21 22:12:08"}
data_source fmp_stable_news_keyword_model_empty
article_count 0
negative_hits 0
positive_hits 0
recomputed_at_score true
sentiment_score_raw 0
source_article_count 10
discarded_article_count 10
sentimentPoints 2

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 2.8 5/110 56% 2.8
資金流 14.8 20/110 74% 14.8
市場環境 10.2 15/110 68% 10.2
催化劑 2 20/110 10% 2
風險管理 8.2 10/110 82% 8.2
技術信號 25.8 30/110 86% 25.8
情緒分析 2 10/110 20% 2

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 30/50
ret_5d 0.0384
max_score 50
max_total 50
raw_total 30
vcp_bonus 0
vol_ratio 1.7043
ret_points 8
vol_points 6
range_ratio 2.0765
volat_points 4
day_range_pct 0.0351
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 8
partial_history false
pullback_points 1
breakout_vol_bonus 1
first_breakout_20d true
return_window_days 5
first_breakout_bonus 2
breakout_quality_points 0

Risk management

level Low
reason risk management score >= 8/10

position

score 1.8

details

atrPct 2.0457
turnoverUsdM 2002.7481
liquidityPoints 0.8
volatilityPoints 1
rrPoints 2

stopLevels

symbol US.PFE
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 25.4158

strength_details

ma_score 2
atr_score 2
rsi_score 3
macd_score 3
volume_score 2
market_adjustment 1
risk_reward_ratio 1.8
stop_loss_percent 4.1
take_profit_price 28.4479
target_multiplier 2.2
technical_strength 2.45
take_profit_percent 7.4
positionPoints 1.8
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.8087
stopLossPercent 4.0913
diversificationPoints 2

Calculation audit log

基本面分析總分: 2.8/5分
資金流分析總分: 14.8/20分
市場環境分析總分: 10.2/15分
催化劑分析: 2/20分
風險管理總分: 8.2/10分
技術信號分析總分: 25.8/30分
情緒分析: 2/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 85.71
atr
atr 0.5421
rule ATR / current price; lower volatility scores higher
score 6
atr_pct 2.05
cci
rule Cursor_18.24 CCI bands
level 超買或超賣風險
score 2
value 224.26
cmf
rule Cursor_18.24 CMF bands
level 輕微流入
score 6
value 0.1283
kdj
d 69.06
j 79.06
k 72.39
rule Cursor_18.24 K/D cross
score 6
signal 強金叉
mfi
rule Cursor_18.24 MFI bands
level 平衡
score 6
value 59.13
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 10
trend 強流入
value 331636200
recentSlope 16286830
previousSlope -9603850
rsi
value 64.58
sar
rule Cursor_18.24 Parabolic SAR
score 8
trend 上升
value 24.917
position SAR喺價下
distancePct 5.97
previousTrend 上升
ma50
value 25.4316
macd
macd 0.2083
trend 強烈看漲
signal 0.1173
histogram 0.0911
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 10
value 25.5314
position 連續5日>VWAP
consecutiveAbove 9
volume
rule Cursor_18.24 volume ratio
level 有量
ratio 1.61
score 6
avgVolume 47040705
currentVolume 75575400
derived
ma20 25.49
ma50 25.4316
prevClose 25.88
avgVolume10 53112100
avgVolume20 47040705
changePercent 2.4
avgVolumeForScore 47040705
ma_cross
ma20 25.49
ma50 25.4316
rule Cursor_18.24 MA20/MA50 cross
cross 接近
score 6
prevMa20 25.4195
prevMa50 25.419
spreadPct 0.23
isVolumeBreakout false
bollinger
lower 24.6884
upper 26.2916
position 上半部
rsi_short
value 71.14
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 1.61

Raw calculation JSON

{
  "risk": {
    "level": "Low",
    "reason": "risk management score >= 8/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.045660377358491,
        "turnoverUsdM": 2002.7481,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 2,
    "stopLevels": {
      "symbol": "US.PFE",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 25.4158,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 2,
        "rsi_score": 3,
        "macd_score": 3,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.8,
      "stop_loss_percent": 4.1,
      "take_profit_price": 28.4479,
      "target_multiplier": 2.2,
      "technical_strength": 2.45,
      "take_profit_percent": 7.4
    },
    "positionPoints": 1.8,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.8087068806493265,
    "stopLossPercent": 4.091320754716982,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 95.8,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 65.8,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 30
  },
  "market": {
    "ma20": 25.49,
    "ma50": 25.4316,
    "close": 26.5,
    "prevClose": 25.88,
    "avgVolume20": 47040705,
    "volumeRatio": 1.61,
    "changePercent": 2.4
  },
  "sources": {
    "catalyst": "fmp_stable_news_keyword_model_empty",
    "sentiment": "fmp_stable_news_keyword_model_empty",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred+database-backfill-market-proxy"
  },
  "barCount": 150,
  "momentum": {
    "max": 50,
    "result": 30,
    "details": {
      "ret_5d": 0.03840125391849525,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 30,
      "vcp_bonus": 0,
      "vol_ratio": 1.7043433746045724,
      "ret_points": 8,
      "vol_points": 6,
      "range_ratio": 2.0765380765483785,
      "volat_points": 4,
      "day_range_pct": 0.035094339622641496,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 8,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 1,
      "first_breakout_20d": true,
      "return_window_days": 5,
      "first_breakout_bonus": 2,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 95.8,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.8,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 56,
        "contribution": 2.8
      },
      {
        "raw": 14.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 74,
        "contribution": 14.8
      },
      {
        "raw": 10.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 68,
        "contribution": 10.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 8.2,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 82,
        "contribution": 8.2
      },
      {
        "raw": 25.8,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 86,
        "contribution": 25.8
      },
      {
        "raw": 2,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 20,
        "contribution": 2
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 65.8,
    "details": [
      "基本面分析總分: 2.8/5分",
      "資金流分析總分: 14.8/20分",
      "市場環境分析總分: 10.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 8.2/10分",
      "技術信號分析總分: 25.8/30分",
      "情緒分析: 2/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.8,
      "資金流": 14.8,
      "市場環境": 10.2,
      "情緒分析": 2,
      "技術信號": 25.8,
      "風險管理": 8.2
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "fmp_stable_news_keyword_model_empty",
              "articleCount": 0,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.5,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 2002.7481,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "良好",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 2.4,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.PFE",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred+database-backfill-market-proxy",
              "vixClose": 16.35
            }
          },
          "trend": {
            "score": 4,
            "details": {
              "qqq": {
                "ma20": 122.32855801433648,
                "ma50": 119.96346877259626,
                "name": "QQQ",
                "close": 124.13713218586749,
                "points": 2
              },
              "spy": {
                "ma20": 113.2768836882191,
                "ma50": 110.87278891017002,
                "name": "SPY",
                "close": 114.45487124539912,
                "points": 2
              },
              "source": "twelvedata+fred+database-backfill-market-proxy"
            }
          },
          "atrPct": 2.045660377358491,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 2,
            "details": {
              "source": "fmp_stable_news_keyword_model_empty",
              "articleCount": 0,
              "negativeHits": 0,
              "positiveHits": 0,
              "sentimentScoreRaw": 0
            }
          },
          "sentimentData": {
            "raw": [],
            "raw_source": [
              {
                "url": "https://seekingalpha.com/article/4916587-jabil-stock-ai-growth-working-valuation-less-forgiving-rating-downgrade",
                "site": "seekingalpha.com",
                "text": "Jabil is downgraded to hold as valuation has rerated to ~23x NTM PE, near its 10-year high. AI-driven revenue growth remains robust, with management guiding for ~$13.6B in FY2026 AI revenue, up 50% year-over-year. JBL's third hyperscaler win and expanded capacity underpin a credible path to >6% operating margin in FY2027.",
                "image": "https://images.financialmodelingprep.com/news/jabil-ai-growth-is-working-but-valuation-is-less-20260621.jpg",
                "title": "Jabil: AI Growth Is Working, But Valuation Is Less Forgiving (Rating Downgrade)",
                "symbol": "JBL",
                "publisher": "Seeking Alpha",
                "publishedDate": "2026-06-21 23:23:58"
              },
              {
                "url": "https://www.globenewswire.com/news-release/2026/06/22/3315020/673/en/ROSEN-A-LEADING-INVESTOR-RIGHTS-LAW-FIRM-Encourages-Verra-Mobility-Corporation-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-VRRM.html",
                "site": "globenewswire.com",
                "text": "NEW YORK, June 21, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Verra Mobility Corporation (NASDAQ: VRRM) between February 24, 2026 and May 26, 2026, inclusive (the “Class Period”), of the important August 4, 2026 lead plaintiff deadline.",
                "image": "https://images.financialmodelingprep.com/news/rosen-a-leading-investor-rights-law-firm-encourages-verra-20260621.jpg",
                "title": "ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Verra Mobility Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - VRRM",
                "symbol": "LAW",
                "publisher": "GlobeNewsWire",
                "publishedDate": "2026-06-21 23:20:00"
              },
              {
                "url": "https://www.fool.com/investing/2026/06/21/could-broadcom-be-the-best-way-to-invest-in-artifi/",
                "site": "fool.com",
                "text": "Broadcom is benefiting as hyperscalers shift toward custom AI chips and networking solutions. AI semiconductor revenue hit $10.8 billion, up 143% year over year in fiscal 2026's second quarter.",
                "image": "https://images.financialmodelingprep.com/news/could-broadcom-be-the-best-way-to-invest-in-20260621.jpg",
                "title": "Could Broadcom Be the Best Way to Invest in Artificial Intelligence Right Now?",
                "symbol": "AVGOP",
                "publisher": "The Motley Fool",
                "publishedDate": "2026-06-21 23:00:00"
              },
              {
                "url": "https://seekingalpha.com/article/4916584-upstart-improving-investment-setup-at-a-10x-pe",
                "site": "seekingalpha.com",
                "text": "Upstart remains a 'Strong Buy' as I expect a multi-year EBITDA upswing driven by AI-powered loan origination and eventual Fed rate cuts. UPST's Q1 transaction volumes surged 61% year-over-year to $3.4B, fueling a 44% Y/Y revenue increase and highlighting robust platform scale. Despite delayed Fed rate cuts, UPST trades at a 44% discount to Fintech peers and a 54% discount to its 3-year average P/E, offering significant revaluation potential if rates fall.",
                "image": "https://images.financialmodelingprep.com/news/upstart-improving-investment-setup-at-a-10x-pe-20260621.jpg",
                "title": "Upstart: Improving Investment Setup At A 10x P/E",
                "symbol": "UPST",
                "publisher": "Seeking Alpha",
                "publishedDate": "2026-06-21 22:53:00"
              },
              {
                "url": "https://www.globenewswire.com/news-release/2026/06/22/3315016/673/en/REGENCELL-DEADLINE-ROSEN-A-LEADING-LAW-FIRM-Encourages-Regencell-Bioscience-Holdings-Limited-Investors-with-Losses-in-Excess-of-100K-to-Secure-Counsel-Before-Important-June-23-Dead.html",
                "site": "globenewswire.com",
                "text": "NEW YORK, June 21, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”), of the important June 23, 2026 lead plaintiff deadline.",
                "image": "https://images.financialmodelingprep.com/news/regencell-deadline-rosen-a-leading-law-firm-encourages-regencell-20260621.jpg",
                "title": "REGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action – RGC",
                "symbol": "LAW",
                "publisher": "GlobeNewsWire",
                "publishedDate": "2026-06-21 22:37:00"
              },
              {
                "url": "https://www.globenewswire.com/news-release/2026/06/22/3315015/673/en/ROSEN-GLOBAL-INVESTOR-COUNSEL-Encourages-Microsoft-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-MSFT.html",
                "site": "globenewswire.com",
                "text": "NEW YORK, June 21, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Microsoft Corporation (NASDAQ: MSFT) between May 1, 2025 and January 28, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 11, 2026.",
                "image": "https://images.financialmodelingprep.com/news/rosen-global-investor-counsel-encourages-microsoft-investors-to-secure-20260621.jpg",
                "title": "ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Microsoft Investors to Secure Counsel Before Important Deadline in Securities Class – MSFT",
                "symbol": "MSFT",
                "publisher": "GlobeNewsWire",
                "publishedDate": "2026-06-21 22:34:00"
              },
              {
                "url": "https://seekingalpha.com/article/4916579-bdj-discount-provides-a-buy-level-for-this-monthly-payer",
                "site": "seekingalpha.com",
                "text": "BlackRock Enhanced Equity Dividend Fund offers diversified, value-oriented exposure with a covered call strategy and an 8.12% yield. BDJ's current -8.22% discount is wider than its historical average, presenting a compelling entry point for income-focused investors. The fund actively manages sector allocations, maintaining financials as its largest sector while increasing technology exposure and selectively capturing gains.",
                "image": "https://images.financialmodelingprep.com/news/bdj-discount-provides-a-buy-level-for-this-monthly-20260621.jpg",
                "title": "BDJ: Discount Provides A 'Buy' Level For This Monthly Payer",
                "symbol": "BDJ",
                "publisher": "Seeking Alpha",
                "publishedDate": "2026-06-21 22:33:00"
              },
              {
                "url": "https://seekingalpha.com/article/4916581-enbridge-stock-boring-beautiful-cash-flow-growth-accelerates-maintain-buy",
                "site": "seekingalpha.com",
                "text": "Enbridge offers stable, predictable earnings and prioritizes long-term EBITDA growth supporting consistent shareholder returns over capital gains. Q1 2026 results showed flat adjusted EBITDA year-over-year at C$5.81B, with segment performance mixed but distributable cash flow per share up despite forex headwinds. Management reaffirmed 2026 guidance: C$20.2–C$20.8B EBITDA (8% CAGR since 2023) and C$5.70–C$6.10 DCF/share, targeting 5% annual medium-term growth.",
                "image": "https://images.financialmodelingprep.com/news/enbridge-boring-is-beautiful-as-cash-flow-growth-accelerates-20260621.jpg",
                "title": "Enbridge: Boring Is Beautiful As Cash Flow Growth Accelerates",
                "symbol": "ENB",
                "publisher": "Seeking Alpha",
                "publishedDate": "2026-06-21 22:32:20"
              },
              {
                "url": "https://seekingalpha.com/article/4916578-henry-schein-smile-because-the-upside-isnt-over",
                "site": "seekingalpha.com",
                "text": "Henry Schein remains a dominant global provider in dental and medical practitioner supplies, with strong market shares and ongoing revenue growth. HSIC's Q1 2026 revenue grew 6.3% year-over-year, driven by robust global dental merchandise and equipment demand, particularly in aging and expanding populations. Profitability metrics are mixed, but adjusted net income and EBITDA are rising; management guides for 3–5% revenue growth and mid-single-digit EBITDA growth in 2026.",
                "image": "https://images.financialmodelingprep.com/news/henry-schein-smile-because-the-upside-isnt-over-20260621.jpg",
                "title": "Henry Schein: Smile Because The Upside Isn't Over",
                "symbol": "HSIC",
                "publisher": "Seeking Alpha",
                "publishedDate": "2026-06-21 22:23:00"
              },
              {
                "url": "https://seekingalpha.com/article/4916569-cynata-therapeutics-limited-cyynf-discusses-phase-ii-acute-graft-versus-host-disease-and",
                "site": "seekingalpha.com",
                "text": "Cynata Therapeutics Limited (CYYNF) Discusses Phase II Acute Graft Versus Host Disease and Phase III Osteoarthritis Trial Results Transcript",
                "image": "https://images.financialmodelingprep.com/news/cynata-therapeutics-limited-cyynf-discusses-phase-ii-acute-graft-20260621.jpg",
                "title": "Cynata Therapeutics Limited (CYYNF) Discusses Phase II Acute Graft Versus Host Disease and Phase III Osteoarthritis Trial Results Transcript",
                "symbol": "CYYNF",
                "publisher": "Seeking Alpha",
                "publishedDate": "2026-06-21 22:12:08"
              }
            ],
            "data_source": "fmp_stable_news_keyword_model_empty",
            "article_count": 0,
            "negative_hits": 0,
            "positive_hits": 0,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0,
            "source_article_count": 10,
            "discarded_article_count": 10
          },
          "sentimentPoints": 2
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 25.8,
        "grade": "優秀",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.6,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.6,
            "vcp_reason": "波幅收縮(6.9%→5.1%);站上MA50;升放量(近10日3日);收盤突破20日高位;Ready=N;Confirm=Y",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 48125666.666666664,
              "down_days": 4,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 50580190,
              "avg_vol_20": 44342825,
              "avg_vol_30": 48125666.666666664,
              "range_pct_10": 0.05056603773584905,
              "range_pct_20": 0.0558490566037736,
              "range_pct_30": 0.06867924528301887,
              "up_expand_ok": true,
              "lookback_used": 79,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": false,
              "up_expand_days": 3,
              "breakout_20d_ok": true,
              "vol_ratio_10_30": 1.0510023757246654,
              "dist_to_20d_high": -0.007221588749524945,
              "down_shrink_days": 2,
              "breakout_level_20d": 26.31,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.7362637362637361
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 4,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 1,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "優秀",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.045660377358491,
              "turnoverUsdM": 2002.7481,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 2,
          "stopLevels": {
            "symbol": "US.PFE",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 25.4158,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 2,
              "rsi_score": 3,
              "macd_score": 3,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.8,
            "stop_loss_percent": 4.1,
            "take_profit_price": 28.4479,
            "target_multiplier": 2.2,
            "technical_strength": 2.45,
            "take_profit_percent": 7.4
          },
          "positionPoints": 1.8,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.8087068806493265,
          "stopLossPercent": 4.091320754716982,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 0.5421,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.05
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 224.26
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1283
    },
    "kdj": {
      "d": 69.06,
      "j": 79.06,
      "k": 72.39,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 59.13
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 331636200,
      "recentSlope": 16286830,
      "previousSlope": -9603850
    },
    "rsi": 64.58,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 24.917,
      "position": "SAR喺價下",
      "distancePct": 5.97,
      "previousTrend": "上升"
    },
    "ma50": 25.4316,
    "macd": {
      "macd": 0.2083332253981247,
      "trend": "強烈看漲",
      "signal": 0.1172812313058748,
      "histogram": 0.09105199409224991
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 25.5314,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 9
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.61,
      "score": 6,
      "avgVolume": 47040705,
      "currentVolume": 75575400
    },
    "derived": {
      "ma20": 25.49,
      "ma50": 25.4316,
      "prevClose": 25.88,
      "avgVolume10": 53112100,
      "avgVolume20": 47040705,
      "changePercent": 2.4,
      "avgVolumeForScore": 47040705
    },
    "ma_cross": {
      "ma20": 25.49,
      "ma50": 25.4316,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 25.4195,
      "prevMa50": 25.419,
      "spreadPct": 0.23,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 24.6884,
      "upper": 26.2916,
      "position": "上半部"
    },
    "rsi_short": 71.14,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.61
    }
  }
}

Raw metrics JSON

{
  "close": 26.5,
  "volume": 75575400,
  "changePercent": 2.4
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.